151 related articles for article (PubMed ID: 27488873)
1. Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer.
Kim M; Keam B; Kim TM; Kim HG; Kim JS; Lee SS; Shin SH; Kim MK; Park KU; Kim DW; Yun HJ; Lee JS; Heo DS
Cancer Res Treat; 2017 Apr; 49(2):416-422. PubMed ID: 27488873
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414).
Tomblyn MB; Goldman BH; Thomas CR; Benedetti JK; Lenz HJ; Mehta V; Beeker T; Gold PJ; Abbruzzese JL; Blanke CD;
J Thorac Oncol; 2012 May; 7(5):906-12. PubMed ID: 22481235
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-naïve patients with metastatic or recurrent squamous cell carcinoma of the esophagus.
Lee DH; Kim HT; Han JY; Lee SY; Yoon SJ; Kim HY; Lee JS
Cancer Chemother Pharmacol; 2008 Jan; 61(1):83-8. PubMed ID: 17468871
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer.
Ilson DH; Saltz L; Enzinger P; Huang Y; Kornblith A; Gollub M; O'Reilly E; Schwartz G; DeGroff J; Gonzalez G; Kelsen DP
J Clin Oncol; 1999 Oct; 17(10):3270-5. PubMed ID: 10506629
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer.
Ilson DH
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):22-5. PubMed ID: 15685830
[TBL] [Abstract][Full Text] [Related]
6. Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study.
Lee SJ; Kim S; Kim M; Lee J; Park YH; Im YH; Park SH
BMC Cancer; 2015 Oct; 15():693. PubMed ID: 26468007
[TBL] [Abstract][Full Text] [Related]
7. Irinotecan plus cisplatin in patients with extensive-disease poorly differentiated neuroendocrine carcinoma of the esophagus.
Okuma HS; Iwasa S; Shoji H; Takashima A; Okita N; Honma Y; Kato K; Hamaguchi T; Yamada Y; Shimada Y
Anticancer Res; 2014 Sep; 34(9):5037-41. PubMed ID: 25202088
[TBL] [Abstract][Full Text] [Related]
8. Toxicity, response rates and survival outcomes of induction cisplatin and irinotecan followed by concurrent cisplatin, irinotecan and radiotherapy for locally advanced esophageal cancer.
Watkins JM; Zauls AJ; Kearney PL; Shirai K; Ruppert BN; Harper JL; Sherman CA; Aguero EG; Reed CE; Sharma AK
Jpn J Clin Oncol; 2011 Mar; 41(3):334-42. PubMed ID: 21084436
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of cetuximab plus cisplatin and irinotecan in patients with cisplatin and irinotecan-refractory metastatic esophagogastric cancer.
Janjigian YY; Ku GY; Campbell JC; Shah MA; Capanu M; Kelsen DP; Ilson DH
Am J Clin Oncol; 2014 Apr; 37(2):126-30. PubMed ID: 23211227
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer.
Knox JJ; Wong R; Visbal AL; Horgan AM; Guindi M; Hornby J; Xu W; Ringash J; Keshavjee S; Chen E; Haider M; Darling G
Cancer; 2010 Sep; 116(17):4023-32. PubMed ID: 20533506
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer.
Shim HJ; Cho SH; Hwang JE; Bae WK; Song SY; Cho SB; Lee WS; Joo YE; Na KJ; Chung IJ
Am J Clin Oncol; 2010 Dec; 33(6):624-8. PubMed ID: 20142726
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer.
Cleary JM; Mamon HJ; Szymonifka J; Bueno R; Choi N; Donahue DM; Fidias PM; Gaissert HA; Jaklitsch MT; Kulke MH; Lynch TP; Mentzer SJ; Meyerhardt JA; Swanson RS; Wain J; Fuchs CS; Enzinger PC
BMC Cancer; 2016 Jul; 16():468. PubMed ID: 27412386
[TBL] [Abstract][Full Text] [Related]
14. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.
Shah MA; Ramanathan RK; Ilson DH; Levnor A; D'Adamo D; O'Reilly E; Tse A; Trocola R; Schwartz L; Capanu M; Schwartz GK; Kelsen DP
J Clin Oncol; 2006 Nov; 24(33):5201-6. PubMed ID: 17114652
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
[TBL] [Abstract][Full Text] [Related]
16. Effective radiochemotherapy with cisplatin and etoposide for the management of patients with locally inoperable and metastatic esophageal carcinoma.
Hejna M; Kornek GV; Schratter-Sehn AU; Zach M; Schoder M; Raderer M; Rosen H; Schiessel R; Scheithauer W
Cancer; 1996 Oct; 78(8):1646-50. PubMed ID: 8859175
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer.
Ruppert BN; Watkins JM; Shirai K; Wahlquist AE; Garrett-Mayer E; Aguero EG; Sherman CA; Reed CE; Sharma AK
Am J Clin Oncol; 2010 Aug; 33(4):346-52. PubMed ID: 19841574
[TBL] [Abstract][Full Text] [Related]
18. A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer.
Kim JY; Do YR; Park KU; Kim MK; Lee KH; Bae SH; Ryoo HM; Baek JH; Song HS
Cancer Chemother Pharmacol; 2010 May; 66(1):31-6. PubMed ID: 19763571
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report.
Govindan R; Read W; Faust J; Trinkaus K; Ma MK; Baker SD; McLeod HL; Perry MC
Oncology (Williston Park); 2003 Sep; 17(9 Suppl 8):27-31. PubMed ID: 14569845
[TBL] [Abstract][Full Text] [Related]
20. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study.
Jagasia MH; Langer CJ; Johnson DH; Yunus F; Rodgers JS; Schlabach LL; Cohen AG; Shyr Y; Carbone DP; Devore RF
Clin Cancer Res; 2001 Jan; 7(1):68-73. PubMed ID: 11205920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
